Groupe Hospitalier Du Havre

The team investigates dMMR/MSI solid tumours that are not colorectal or endometrial, testing a novel immunotherapy to enhance progression‑free survival compared with standard care.

• Checkpoint inhibitor development
• Biomarker‑guided patient enrollment
• First‑line therapeutic strategies for rare MSI‑high cancers

This work at Groupe Hospitalier Du Havre aims to broaden effective options for patients with advanced, metastatic disease.

Researchers assess the safety of stopping dupilumab after long‑term use, seeking to prove non‑inferiority of withdrawal versus continued therapy in severe asthma management.

• Long‑term biologic therapy evaluation
• Strategic treatment interruption studies
• Outcome measures for asthma control and exacerbations

The findings aim to inform clinicians on optimal maintenance strategies for chronic respiratory disease at this French hospital.